Rhythm Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell RYTM and other ETFs, options, and stocks.

About RYTM

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. 

CEO
David P. Meeker
CEODavid P. Meeker
Employees
283
Employees283
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
2008
Founded2008
Employees
283
Employees283

RYTM Key Statistics

Market cap
7.78B
Market cap7.78B
Price-Earnings ratio
-34.74
Price-Earnings ratio-34.74
Dividend yield
Dividend yield
Average volume
626.98K
Average volume626.98K
High today
$113.53
High today$113.53
Low today
$106.08
Low today$106.08
Open price
$107.50
Open price$107.50
Volume
491.51K
Volume491.51K
52 Week high
$122.20
52 Week high$122.20
52 Week low
$45.91
52 Week low$45.91

Stock Snapshot

With a market cap of 7.78B, Rhythm Pharmaceuticals(RYTM) trades at $113.34. The stock has a price-to-earnings ratio of -34.74.

On 2026-01-14, Rhythm Pharmaceuticals(RYTM) stock traded between a low of $106.08 and a high of $113.53. Shares are currently priced at $113.34, which is +6.8% above the low and -0.2% below the high.

Rhythm Pharmaceuticals(RYTM) shares are trading with a volume of 491.51K, against a daily average of 626.98K.

In the last year, Rhythm Pharmaceuticals(RYTM) shares hit a 52-week high of $122.20 and a 52-week low of $45.91.

In the last year, Rhythm Pharmaceuticals(RYTM) shares hit a 52-week high of $122.20 and a 52-week low of $45.91.

RYTM News

Simply Wall St 5d
Rhythm Pharmaceuticals Valuation Check As IMCIVREE Growth And Key Trial Readouts Approach

Rhythm Pharmaceuticals (RYTM) is back in focus after issuing preliminary 2025 guidance, highlighting IMCIVREE revenue estimates and upcoming trial milestones th...

Rhythm Pharmaceuticals Valuation Check As IMCIVREE Growth And Key Trial Readouts Approach
TipRanks 5d
Rhythm Pharmaceuticals Reports Strong Preliminary 2025 IMCIVREE Revenue

Claim 70% Off TipRanks Premium Rhythm Pharmaceuticals ( (RYTM) ) has shared an announcement. On January 9, 2026, Rhythm Pharmaceuticals reported preliminary,...

Analyst ratings

94%

of 16 ratings
Buy
93.8%
Hold
6.3%
Sell
0%

People also own

Based on the portfolios of people who own RYTM. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .